Haleon (NYSE:HLN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Haleon (NYSE:HLN) from a hold rating to a buy rating in a research report report published on Saturday.

A number of other research analysts also recently issued reports on HLN. Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Argus raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Trading Down 1.5%

Shares of HLN opened at $10.08 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The stock has a market cap of $44.88 billion, a PE ratio of 25.83 and a beta of 0.18. Haleon has a 1 year low of $8.71 and a 1 year high of $11.42. The stock has a 50 day simple moving average of $10.53 and a 200-day simple moving average of $9.88.

Haleon Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be issued a $0.1307 dividend. This represents a dividend yield of 251.0%. The ex-dividend date is Friday, April 10th. Haleon’s payout ratio is 28.21%.

Institutional Investors Weigh In On Haleon

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of Haleon in the 4th quarter valued at approximately $187,000. AQR Capital Management LLC lifted its stake in Haleon by 22.5% in the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after purchasing an additional 17,720 shares during the last quarter. Focus Partners Wealth lifted its stake in Haleon by 7.6% in the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after purchasing an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the period. Finally, Creative Planning increased its position in Haleon by 16.4% during the second quarter. Creative Planning now owns 454,621 shares of the company’s stock worth $4,714,000 after buying an additional 64,021 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.